Placebo-controlled Phase 2 study will evaluate SAT-3247 treatment over three months among ambulatory children with Duchenne- Study endpoints include safety and tolerability, effect on muscle force and ...
Dyne Therapeutics intends to submit a biologics licence application to the FDA for accelerated approval in Q2 2026.
A new article reflects on how two generations of scientists reshaped thinking on aging, linking hormonal regulation in the brain to molecular growth pathways. Mikhail Blagosklonny spent his career ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback